● neutral
Impact
PhasePilot study (proof-of-concept, equivalent to early Phase 1/2)
Time to marketKB113 is in early-stage development with no registered Phase 2/3 trial and no defined regulatory timeline. The company is in discussions with the FDA to determine the clinical development plan. If a pivotal program is agreed upon and initiated in 2027, potential approval would likely be several years away, barring a breakthrough or accelerated pathway.
KB113 Updated Nov 2
What to watch
Watch for Krystal Biotech's announcement of FDA alignment on KB113's clinical development plan, which will define whether the program advances into a registrational trial or requires additional dose-finding studies. The small pilot (n=3) provides proof-of-concept but the regulatory path and timeline remain undefined, making KB113 a pipeline story rather than a near-term catalyst.
Bull case
- 83.1% of assessed BCC lesions (69/83) regressed across all 3 patients, including 40 of 47 non-injected lesions, demonstrating a systemic abscopal immune response that could differentiate KB113 from local therapies.
- All 3 biopsied lesions with >=90% regression showed histologically confirmed complete clearance, and all 22 adverse events were mild or moderate with no serious events, suggesting a favorable safety profile.
- Gorlin syndrome patients face a lifetime burden of multiple BCCs requiring repeated surgeries; a well-tolerated intratumoral immunotherapy that shrinks both injected and distant lesions could address a significant unmet need.
Bear case
- The entire pilot study enrolled only 3 patients, far too small to establish efficacy or safety; larger trials could fail to replicate the results.
- KB113 is a low-dose formulation of KB707, which itself is still in Phase 1/2 testing (OPAL-1 study); any safety or manufacturing issues with KB707 could affect KB113.
- Existing oral hedgehog-pathway inhibitors (vismodegib/Erivedge, sonidegib/Odomzo) are already approved for BCC in Gorlin syndrome, though they are poorly tolerated; KB113 must demonstrate a clear tolerability and efficacy advantage to displace them.